Summary of COVID-19 AZD5156 studies

1. Haidar et al., Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)

57 patient AZD5156 prophylaxis RCT: 139% higher mortality (p=1).
RCT 57 patients showing no significant differences with AZD5156 (sipavibart + cilgavimab).
Jun 2026, NCT05648110, https://clinicaltrials.gov/study/NCT05648110, https://c19p.org/haidar3